Therefore, modifying MNB-Pyra with the 7D12-fGly nanobody enables MNB-Pyra Nbs to specifically target EGFR-overexpressing cancer cells, thereby minimizing potential side effects during cancer therapy. The gene discussed is EGFR; the disease is cancer.